Private Advisor Group’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.4M Buy
52,611
+764
+1% +$147K 0.05% 390
2025
Q4
$9.53M Buy
51,847
+602
+1% +$106K 0.04% 409
2025
Q3
$7.86M Buy
51,245
+3,823
+8% +$579K 0.04% 456
2025
Q2
$6.63M Buy
47,422
+15,890
+50% +$2.23M 0.04% 469
2025
Q1
$4.64M Sell
31,532
-129
-0.4% -$18.7K 0.03% 563
2024
Q4
$4.15M Sell
31,661
-601
-2% -$84.1K 0.02% 584
2024
Q3
$5.03M Sell
32,262
-291
-0.9% -$47K 0.03% 522
2024
Q2
$5.08M Buy
32,553
+2,278
+8% +$343K 0.03% 480
2024
Q1
$4.1M Sell
30,275
-262
-0.9% -$34.7K 0.03% 524
2023
Q4
$4.11M Sell
30,537
-1,944
-6% -$253K 0.03% 502
2023
Q3
$4.4M Sell
32,481
-2,281
-7% -$312K 0.04% 432
2023
Q2
$4.98M Sell
34,762
-1,169
-3% -$172K 0.04% 401
2023
Q1
$4.99M Buy
35,931
+830
+2% +$112K 0.05% 378
2022
Q4
$3.42M Buy
35,101
+778
+2% +$97.6K 0.17% 127
2022
Q3
$3.76M Sell
34,323
-16,664
-33% -$2.11M 0.04% 421
2022
Q2
$6.74M Buy
50,987
+1,375
+3% +$180K 0.06% 319
2022
Q1
$6.58M Buy
49,612
+1,321
+3% +$158K 0.05% 354
2021
Q4
$5.63M Sell
48,291
-36,835
-43% -$4.33M 0.04% 414
2021
Q3
$10.2M Buy
85,126
+43,709
+106% +$5.09M 0.07% 296
2021
Q2
$4.96M Buy
41,417
+42
+0.1% +$4.61K 0.04% 407
2021
Q1
$4.11M Buy
41,375
+21,218
+105% +$2.13M 0.04% 436
2020
Q4
$2.02M Buy
20,157
+4,233
+27% +$448K 0.02% 661
2020
Q3
$1.72M Buy
15,924
+1,505
+10% +$167K 0.02% 608
2020
Q2
$1.52M Buy
14,419
+878
+6% +$90.7K 0.02% 612
2020
Q1
$1.21M Buy
13,541
+847
+7% +$79.7K 0.02% 595
2019
Q4
$1.26M Sell
12,694
-11,193
-47% -$1.05M 0.02% 678
2019
Q3
$2.23M Buy
23,887
+2,261
+10% +$196K 0.03% 508
2019
Q2
$1.74M Buy
21,626
+8,002
+59% +$627K 0.03% 527
2019
Q1
$1.1M Buy
13,624
+3,161
+30% +$249K 0.02% 620
2018
Q4
$795K Sell
10,463
-6,066
-37% -$474K 0.02% 660
2018
Q3
$1.31M Sell
16,529
-15,711
-49% -$1.19M 0.03% 569
2018
Q2
$2.26M Buy
32,240
+23,232
+258% +$1.67M 0.04% 254
2018
Q1
$630K Sell
9,008
-17,028
-65% -$1.18M 0.02% 573
2017
Q4
$1.83M Buy
26,036
+6,389
+33% +$431K 0.08% 258
2017
Q3
$1.35M Buy
19,647
+3,434
+21% +$217K 0.03% 485
2017
Q2
$1.09M Sell
16,213
-14,401
-47% -$940K 0.03% 518
2017
Q1
$1.66M Buy
30,614
+18,625
+155% +$1.08M 0.05% 390
2016
Q4
$674K Buy
11,989
+3,335
+39% +$189K 0.02% 630
2016
Q3
$565K Sell
8,654
-718
-8% -$46.9K 0.02% 607
2016
Q2
$564K Buy
9,372
+1,344
+17% +$78.1K 0.02% 587
2016
Q1
$452K Sell
8,028
-872
-10% -$52.4K 0.02% 611
2015
Q4
$604K Buy
8,900
+1,045
+13% +$68.5K 0.03% 536
2015
Q3
$500K Buy
7,855
+102
+1% +$6.71K 0.03% 574
2015
Q2
$494K Buy
7,753
+166
+2% +$11.4K 0.02% 596
2015
Q1
$519K Sell
7,587
-296
-4% -$20.6K 0.03% 546
2014
Q4
$555K Sell
7,883
-4,194
-35% -$300K 0.04% 502
2014
Q3
$863K Buy
12,077
+10
+0.1% +$732 0.06% 360
2014
Q2
$897K Sell
12,067
-578
-5% -$41.8K 0.08% 314
2014
Q1
$820K Sell
12,645
-445
-3% -$28.7K 0.09% 284
2013
Q4
$777K Buy
+13,090
New +$711K 0.09% 284

Other funds holding AZN

Private Advisor Group's AZN Position: Q1 2026 in Review

Private Advisor Group increased its AstraZeneca (AZN) stake by 1.5% in Q1 2026, buying an estimated $147K and bringing the position to 52,611 shares worth $10.4M. The position accounts for 0.05% of the portfolio, ranked #390.

Private Advisor Group first reported a position in AZN in Q4 2013 and has held it in 50 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Private Advisor Group held 52,611 shares of AstraZeneca worth $10.4M as of Q1 2026.
  • Private Advisor Group bought 764 AstraZeneca shares in Q1 2026, an estimated $147K.
  • AstraZeneca made up 0.05% of Private Advisor Group's portfolio in Q1 2026, its #390 holding.
  • Private Advisor Group first reported a position in AstraZeneca in Q4 2013 and has held it in 50 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.